Evaluation of T1rho Magnetic Resonance Imaging for Diagnosis of Cartilage Lesions in Hips With Developmental Dysplasia

Recruiting in Palo Alto (17 mi)

Overseen byPaul Beaule, MD, FRCSC

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Ottawa Hospital Research Institute

No Placebo Group

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?One of the leading causes of hip arthritis is developmental dysplasia of the hip (DDH). DDH can lead to major damage in the hip joint and may result in hip arthritis later in life. Patients recruited into this study will be undergoing corrective hip surgery within the next 6 months with a goal of preventing further hip problems down the road. This study is being done to see how well a newer type of Magnetic Resonance Imaging (MRI) detects hip cartilage damage compared to an older but well validated MRI method.

Eligibility Criteria

Inclusion Criteria

patients with a diagnosis of developmental dysplasia of the hip (DDH)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Developmental dysplasia of the hip (DDH)Experimental Treatment1 Intervention

Patients will complete 2 magnetic resonance imaging (MRI): T1-rho and dGEMRIC. The T1-rho MRI does not require the injection of a contrast agent, while the dGEMRIC MRI requires a gadolinium injection to visualize cartilage in the hip.